University of Kentucky Companies

College of Medicine

20/20 GeneSystems Inc.
www.2020gene.com

Enzymax LLC
www.enzymax.net
Manufactures proteins and enzymes for biomedical research, and offers custom protein purification and custom DNA constructions using advanced biotechnologies. Based on the research of Zhigang Wang, toxicology.

HiberNetics
www.hibernetics.com
HiberNetics is identifying the clinical potential of opioid peptides, referred to as deltorphins, in treating stroke. Current research indicates that the use of these peptides within minutes to hours after a stroke can provide a dramatic new approach to neuroprotection. HiberNetics has demonstrated that these deltorphins can also reduce cerebral and myocardial ischemic injury and enhance survival following severe hemorrhage. Based on research by Peter Oeltgen, medicine.

i-Glyco Inc.
www.iglyko.com
i-Glyco Inc. is developing glucose monitoring technology. Located in California, i-Glyco Inc. is based on research by Sylvia Daunert, chemistry.

IP Pharmaceuticals LLC
Guangxiang Luo 859/257-5577
IP Pharmaceuticals is developing stable cell lines that produce HCV (hepatitis C virus). Based on the research of Guangxiang Luo, MD, MPH, in the Department of Microbiology, Immunology and Molecular Genetics.

Nano-Mite Technologies LLC
www.nano-mite.com
Nano-Mite, based on the research of Patrick G. Sullivan, with UK’s Spinal Cord & Brain Injury Research Center (SCoBIRC) and the Department of Anatomy & Neurobiology, is focused on controlling obesity—in both humans and pets—using nanotechnology. Nano-Mite has developed, and is currently testing, a nano-scale medical device that serves as mitochondrial uncouplers to increase metabolism and result in weight loss.

OsteoRegeneron
John Williams 859/323-5049
OsteoRegeneron is built around three patents obtained for a novel bone chemokine that stimulates osteoblast differentiation. This product will represent the first non-hormonal anabolic agent to increase bone density.

Quanteon LLC
www.quanteon.cc
Develops microsensor technologies to measure neurochemicals, including dopamine, norepinephrine, serotonin, nitric oxide, and glutamate. Microsensor development and fabrication, Windows-based software for data recording and analysis, instrumentation development, and microelectronic interfaces. Based on the research of Greg Gerhardt, medicine.

Stallion Therapeutics Inc.
Ed Hall 859/425-1043
Stallion Therapeutics is a Lexington based start-up pharmaceutical company interested in developing neuroprotective and neurorestorative compounds for traumatic brain injury, spinal cord injury and other acute neurological disorders. The founder of Stallion is Dr. Edward D. Hall,  Director of the University of Kentucky Spinal Cord & Brain Injury Research Center (SCoBIRC) and SCoBIRC Endowed Professor of Anatomy & Neurobiology, Neurology and Neurosurgery. A pending STTR grant proposal involves testing the efficacy of certain compounds developed in collaboration with NeurOp Inc. (www.neuropinc.com) in models of traumatic brain injury. Stallion will commence its own medicinal chemistry efforts in 2008.

ViroTac LLC
Guangxiang Luo 859/257-5577
ViroTac is developing antibodies and viral enzymes. Based on the research of Guangxiang Luo, MD, MPH, in the Department of Microbiology, Immunology and Molecular Genetics.